share_log

復星醫藥：海外監管公告 - 關於以集中競價交易方式首次回購A股的公告

FOSUN PHARMA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

Hong Kong Stock Exchange ·  Jun 25 18:33
Summary by Futu AI
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年6月25日宣布，根據其回購方案，公司已通過集中競價交易方式首次回購A股股份。該回購行動是在2024年3月26日至9月25日的回購期限內進行，回購資金總額預計為人民幣10,000萬元至20,000萬元之間。此次回購共計1,160,800股，約占公司總股本的0.0434%，總金額為人民幣2,572.26萬元。回購的平均價格為22.16元/股，最高價為22.25元/股，最低價為22.03元/股。該舉措旨在用於員工持股計劃或股權激勵，並符合相關法律法規及回購方案的要求。復星醫藥將根據市場情況選擇時機繼續回購A股，並及時履行信息披露義務。
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年6月25日宣布，根據其回購方案，公司已通過集中競價交易方式首次回購A股股份。該回購行動是在2024年3月26日至9月25日的回購期限內進行，回購資金總額預計為人民幣10,000萬元至20,000萬元之間。此次回購共計1,160,800股，約占公司總股本的0.0434%，總金額為人民幣2,572.26萬元。回購的平均價格為22.16元/股，最高價為22.25元/股，最低價為22.03元/股。該舉措旨在用於員工持股計劃或股權激勵，並符合相關法律法規及回購方案的要求。復星醫藥將根據市場情況選擇時機繼續回購A股，並及時履行信息披露義務。
Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.) announced on June 25, 2024 that, under its buyback plan, the company has repurchased A-shares for the first time through centralized bidding trading. The buyback was carried out within the buyback period from March 26, 2024 to September 25, 2024, with a total buyback capital expected to be between RMB 100 million and RMB 200 million. A total of 1,160,800 shares were bought back, accounting for approximately 0.0434% of the company's total share capital, with a total amount of RMB 25,722,600. The average buyback price was RMB 22.16/share, the highest price was RMB 22.25/share, and the lowest price was RMB 22.03/share. This move is intended for employee shareholding plans or stock-based incentive, and complies with relevant laws and regulations as well as the requirements of the buyback plan. Fosun Pharma will continue to repurchase A-shares based on market conditions and fulfill information disclosure obligations in a timely manner.
Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.) announced on June 25, 2024 that, under its buyback plan, the company has repurchased A-shares for the first time through centralized bidding trading. The buyback was carried out within the buyback period from March 26, 2024 to September 25, 2024, with a total buyback capital expected to be between RMB 100 million and RMB 200 million. A total of 1,160,800 shares were bought back, accounting for approximately 0.0434% of the company's total share capital, with a total amount of RMB 25,722,600. The average buyback price was RMB 22.16/share, the highest price was RMB 22.25/share, and the lowest price was RMB 22.03/share. This move is intended for employee shareholding plans or stock-based incentive, and complies with relevant laws and regulations as well as the requirements of the buyback plan. Fosun Pharma will continue to repurchase A-shares based on market conditions and fulfill information disclosure obligations in a timely manner.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.